Abstract
4597 Background: Patients with prostate cancer receiving androgen deprivation therapy (ADT) may experience side effects including bone loss (osteoporosis), hot flashes, and gynecomastia. Bone loss is of particular significance as a bone fracture in this population has been associated with a significant decrease in length of survival. Toremifene citrate (Acapodene™), a selective estrogen receptor modulator (SERM), has the potential to ameliorate many of these side effects of ADT and to improve quality of life. Methods: 46 consenting patients who had been on ADT for at least 12 months were randomized to 20 mg, 40 mg, or 60 mg of toremifene citrate or placebo administered orally once daily for 6 months. Assessments included bone mineral density (BMD) determination by dual energy X-ray absorptiometry (DEXA), bone turnover markers, and hot flashes. Results: Toremifene was well tolerated at all doses studied. Based on our own observations and recent reports in the literature, the antiandrogen bicalutamide can a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
